• 1
    OHE-IFPMA. Health Economic Evaluation Database (HEED). London: Office for Health Economics, 1999.
  • 2
    Drummond MF, Rutten FFH, Brenna A, et al. Economic evaluation of pharmaceuticals: a European perspective. Pharmacoeconomics 1993;4: 17386.
  • 3
    Drummond MF, Jönsson B, Rutten FFH. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997;40: 199215.
  • 4
    Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). Oxford: Oxford University Press, 1997.
  • 5
    Elsinga E, Rutten FFH. Economic evaluation in support of national health policy: the case of The Netherlands. Soc Sci Med 1997;45: 60720.
  • 6
    Le Pen C. Pharmaceutical economy and the economic assessment of drugs in France. Soc Sci Med 1997;45: 63743.
  • 7
    Badia X, Segú JL, Garcia F, et al. Análisis coste-eficacia des tratamiento con anticuerpos monoclonales antiendotoxina en la sepsis por gram negativos. Revista Med Clinica 1993;100: 849.
  • 8
    Drummond MF. Evidence-based medicine and cost-effectiveness: uneasy bedfellows? Evidence-Based Med 1998;3: 133.
  • 9
    Poulsen P, Christiansen T, Alban A, et al. Model for health economic analysis—urine infections of children. In: Model for a Clinical Practice Programme (Reference Programme) Health Economic Appendix National Board of Health, Copenhagen, 1992.
  • 10
    Eccles M, Freemantle N, Mason J, et al. North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. Br Med J 1998;316: 136975.
  • 11
    Mason JM, Eccles M, Freemantle N, et al. A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines. Health Policy 1999;47: 3752.